NASDAQ:MGX Metagenomi (MGX) Stock Price, News & Analysis $1.92 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.92 +0.01 (+0.26%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Metagenomi Stock (NASDAQ:MGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Metagenomi alerts:Sign Up Key Stats Today's Range$1.82▼$1.9750-Day Range$1.42▼$2.5252-Week Range$1.23▼$4.92Volume361,689 shsAverage Volume700,950 shsMarket Capitalization$71.77 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingBuy Company Overview Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California. Read More Metagenomi Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreMGX MarketRank™: Metagenomi scored higher than 52% of companies evaluated by MarketBeat, and ranked 509th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMetagenomi has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMetagenomi has only been the subject of 2 research reports in the past 90 days.Read more about Metagenomi's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Metagenomi are expected to decrease in the coming year, from ($2.46) to ($2.52) per share.Price to Book Value per Share RatioMetagenomi has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Metagenomi's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.10% of the float of Metagenomi has been sold short.Short Interest Ratio / Days to CoverMetagenomi has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Metagenomi has recently decreased by 10.14%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMetagenomi does not currently pay a dividend.Dividend GrowthMetagenomi does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.10% of the float of Metagenomi has been sold short.Short Interest Ratio / Days to CoverMetagenomi has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Metagenomi has recently decreased by 10.14%, indicating that investor sentiment is improving significantly. News and Social Media1.1 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Metagenomi this week, compared to 5 articles on an average week.Search Interest5 people have searched for MGX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Metagenomi to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Metagenomi insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,800.00 in company stock.Percentage Held by Insiders17.80% of the stock of Metagenomi is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Metagenomi's insider trading history. Receive MGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metagenomi and its competitors with MarketBeat's FREE daily newsletter. Email Address MGX Stock News HeadlinesMetagenomi (MGX) Presents Latest in Gene Editing TechnologiesJuly 29, 2025 | msn.comMetagenomi Showcases Advanced AI-Enhanced Gene Editing for Neurological Disorders at ASGCT MeetingJuly 14, 2025 | msn.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 8 at 2:00 AM | Porter & Company (Ad)Metagenomi, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMay 16, 2025 | finance.yahoo.com2MGX : Demystifying Metagenomi: Insights From 4 Analyst ReviewsMay 15, 2025 | benzinga.comMetagenomi Reports Promising Hemophilia A Study ResultsMay 14, 2025 | tipranks.comMetagenomi, Inc.: Metagenomi Reports Business Updates and First Quarter 2025 Financial ResultsMay 14, 2025 | finanznachrichten.deMetagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025May 14, 2025 | globenewswire.comSee More Headlines MGX Stock Analysis - Frequently Asked Questions How have MGX shares performed this year? Metagenomi's stock was trading at $3.61 on January 1st, 2025. Since then, MGX stock has decreased by 46.8% and is now trading at $1.92. How were Metagenomi's earnings last quarter? Metagenomi, Inc. (NASDAQ:MGX) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by $0.06. The business earned $4.13 million during the quarter, compared to the consensus estimate of $8.75 million. Metagenomi had a negative net margin of 172.21% and a negative trailing twelve-month return on equity of 31.21%. When did Metagenomi IPO? Metagenomi (MGX) raised $94 million in an initial public offering (IPO) on Friday, February 9th 2024. The company issued 6,250,000 shares at $15.00 per share. Who are Metagenomi's major shareholders? Metagenomi's top institutional investors include Peapod Lane Capital LLC (1.36%), Geode Capital Management LLC (0.79%), Good Life Advisors LLC (0.54%) and Vanguard Personalized Indexing Management LLC (0.06%). Insiders that own company stock include Brian C Thomas, Holdings A/S Novo, Sarah B Noonberg and Pamela Wapnick. View institutional ownership trends. How do I buy shares of Metagenomi? Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Metagenomi own? Based on aggregate information from My MarketBeat watchlists, some other companies that Metagenomi investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/13/2025Today8/08/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MGX Previous SymbolNASDAQ:MGX CIK1785279 Webwww.metagenomi.co Phone510-871-4880FaxN/AEmployees236Year FoundedN/APrice Target and Rating Average Price Target for Metagenomi$13.00 High Price Target$17.00 Low Price Target$7.00 Potential Upside/Downside+577.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($2.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$78.06 million Net Margins-172.21% Pretax Margin-184.18% Return on Equity-31.21% Return on Assets-22.21% Debt Debt-to-Equity RatioN/A Current Ratio5.85 Quick Ratio5.85 Sales & Book Value Annual Sales$52.29 million Price / Sales1.37 Cash FlowN/A Price / Cash FlowN/A Book Value$6.28 per share Price / Book0.31Miscellaneous Outstanding Shares37,380,000Free Float30,727,000Market Cap$71.77 million OptionableN/A Beta-0.12 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:MGX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.